# ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

> **NCT03903835** · PHASE3 · RECRUITING · sponsor: **Karolinska Institutet** · enrollment: 750 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

## Interventions

- **DRUG:** Enzalutamide Oral Capsule
- **DRUG:** Abiraterone Oral Tablet
- **DRUG:** Carboplatin
- **DRUG:** Cabazitaxel 60 mg Solution for Injection
- **DRUG:** Docetaxel Injectable Solution
- **DRUG:** Radium Chloride Ra-223
- **DRUG:** Niraparib plus Abiraterone acetate plus Prednisone
- **DRUG:** Capivasertib plus Docetaxel
- **DRUG:** Apalutamide
- **DRUG:** Darolutamide

## Key facts

- **NCT ID:** NCT03903835
- **Lead sponsor:** Karolinska Institutet
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-02-01
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 750 (ESTIMATED)
- **Last updated:** 2025-04-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03903835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03903835, "ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03903835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*